Rhelion Life Sciences Corp. (CSE: RHEL; OTCQB: TRUFF) said its wholly owned subsidiary, Filament Health Corp., has entered a license agreement with Toronto’s University Health Network to supply PEX010 for a randomized clinical trial studying psilocybin as a potential treatment for depression in people with Parkinson’s disease.
The investigator-initiated study, called PSI-PARK, will be sponsored and conducted by UHN under principal investigator Dr. Joshua Rosenblat. Filament will provide PEX010 as the investigational drug product but will not sponsor, manage or conduct the trial.
Rhelion did not disclose the agreement’s financial terms, planned enrollment, study start date or expected data-readout timeline.
PEX010 is Filament’s standardized, GMP-manufactured botanical psilocybin candidate. It is available in doses ranging from 0.5 milligrams to 25 milligrams and is being supplied to academic research and compassionate-access programs. Rhelion acquired Filament on April 30, adding its manufacturing capabilities, clinical infrastructure and portfolio of 76 issued patents.
Scientific evidence for psilocybin in Parkinson’s disease remains preliminary. A separate 2025 open-label pilot enrolled 12 participants with mild-to-moderate Parkinson’s disease and depression or anxiety. Participants received two psilocybin doses combined with psychotherapy.
Researchers reported no serious adverse events and improvements in depression and anxiety measures that persisted through the three-month assessment. However, the study had no placebo group, involved a small sample and could not separate the effects of psilocybin from psychotherapy. Its authors said randomized controlled trials were needed to assess efficacy.
The UHN agreement provides Rhelion with another research use for PEX010 but does not establish the candidate’s safety, efficacy or commercial potential. Rhelion’s announcement also states that the company is not responsible for conducting PSI-PARK. The trial could face enrollment, regulatory or scheduling delays and may not produce clinically meaningful results.
Rhelion, formerly Red Light Holland, reported C$8.47 million in cash and C$4.20 million in revenue for the fiscal year ended March 31, 2026. Revenue declined 15% from the previous year, while its adjusted EBITDA loss widened to C$2.93 million from C$2.53 million. These financial figures predate the April 30 Filament acquisition and do not reflect a full reporting period for the combined company.
Sources
- Rhelion signs UHN agreement for the PSI-PARK clinical trial
- Rhelion fiscal 2026 financial and operational results
- Rhelion Life Sciences CSE issuer profile
- 2025 Parkinson’s disease psilocybin pilot study
Editorial Disclosure
This article is based entirely on publicly available information, including company press releases, regulatory filings, exchange information and peer-reviewed research. Securities discussed or referenced include Rhelion Life Sciences Corp. (CSE: RHEL; OTCQB: TRUFF; FSE: 4YX). Biotech Stocks Daily has not received compensation from any company mentioned, its management, investor relations representatives or any third party for this specific article. Biotech Stocks Daily may have current or past paid business relationships with other companies, which does not influence the content or conclusions of this article. No staff member or principal of Biotech Stocks Daily holds a position in any security mentioned at the time of publication.
Sources used were Rhelion Life Sciences’ August 14, 2026 announcement distributed through Newsfile Corp.; the company’s fiscal 2026 results released July 29, 2026; the Canadian Securities Exchange issuer profile accessed August 15, 2026; and a 2025 peer-reviewed pilot study published in Neuropsychopharmacology.
As of March 31, 2026, Rhelion reported C$8.47 million in cash, C$4.20 million in annual revenue and a C$2.93 million adjusted EBITDA loss. These figures predate the acquisition of Filament Health. Rhelion did not disclose the UHN agreement’s financial value, the trial’s planned enrollment, its start date or a data-readout timeline. UHN—not Rhelion or Filament—is sponsoring and conducting the study. PEX010 remains investigational, and positive or commercially meaningful results are not assured.
Financial and share-count information reflects the dates stated above and may change. No market-price data was used in this article. Readers should verify current filings and market information before making decisions.
These are speculative investments carrying significant risk, including potential total loss of capital. Coverage on Biotech Stocks Daily is provided for informational and educational purposes only. Biotech Stocks Daily is not a registered investment advisor. Nothing in this article constitutes financial, investment or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information, please see our full DISCLAIMER.
